On Wednesday, Capricor Therapeutics (NASDAQ:CAPR) shares maintained its Buy rating and a $40.00 price target from H.C. Wainwright. The firm's endorsement follows Capricor's announcement on September 17 of an expanded partnership with Nippon Shinyaku for the commercialization and distribution of its lead product candidate, deramiocel, in Europe. This treatment is aimed at addressing Duchenne muscular dystrophy (DMD).
The new agreement enhances the existing collaboration between Capricor and Nippon Shinyaku, which began with a partnership in January 2022 for the U.S. market and was extended in February 2023 to include exclusive rights in Japan.
The latest expansion is seen as a stepping stone for potential future global outreach. Under the terms, Capricor is responsible for the development and manufacturing of deramiocel, pending approval in the European Union, United Kingdom, and additional regional markets, while Nippon Shinyaku will handle sales and distribution.
Capricor is set to receive a $20 million upfront payment once the agreement is executed, with the possibility of earning up to $715 million more in development and sales milestones. They will also gain a double-digit percentage of product revenues.
Moreover, Nippon Shinyaku has committed to buying approximately $15 million worth of Capricor common stock, which amounts to 2,798,507 shares, at a 20% premium to the 60-day volume-weighted average price, which equates to $5.36 per share.
The financial aspects of this partnership are significant for Capricor, providing the company with a substantial immediate cash infusion and the prospect of further milestone payments. This arrangement also includes a notable investment in Capricor's equity by Nippon Shinyaku, which indicates confidence in Capricor's future prospects and deramiocel's potential in the DMD market.
This extended partnership is expected to be finalized in the fourth quarter of 2024. It not only solidifies Capricor's financial position but also sets the stage for the company's preparations for a potential commercial launch, scaling up manufacturing, and further product development in Europe. H.C. Wainwright's reiteration of the Buy rating and price target reflects optimism about the company's path forward.
In other recent news, Capricor Therapeutics has made significant strides in the biopharmaceutical sector. The firm's primary focus is the development of deramiocel, a potential treatment for Duchenne muscular dystrophy. Capricor recently finalized terms for the European commercialization of deramiocel with its existing partner, Nippon Shinyaku. This agreement is expected to extend Capricor's cash runway into 2026.
In addition to this, the company has secured a financial agreement with Nippon Shinyaku, totaling up to $35 million, which includes a $15 million equity investment and an upfront payment of $20 million. This funding is anticipated to support the development and global distribution of deramiocel.
Despite reporting a net loss of approximately $11 million for Q2 2024, the company generated revenue of around $4 million and maintains a strong cash position of $29.5 million. Moreover, Oppenheimer has increased its price target for Capricor to $15, maintaining an Outperform rating on the stock.
The company is also preparing for a potential commercial launch of deramiocel and is in advanced partnership discussions for distribution in Europe. These recent developments highlight Capricor's ongoing progress in the biopharmaceutical sector.
InvestingPro Insights
In light of Capricor Therapeutics' (NASDAQ:CAPR) recent partnership expansion and the positive outlook from H.C. Wainwright, it's pertinent to consider the company's financial health and market performance. According to InvestingPro data, Capricor holds a market capitalization of $165.3 million and has experienced a remarkable revenue growth rate of 187.15% over the last twelve months as of Q2 2024. Despite this growth, the company's P/E ratio stands at -5.39, reflecting its current lack of profitability.
InvestingPro Tips suggest that Capricor is quickly burning through cash, which is a critical factor to monitor given the company's ambitious development and manufacturing goals for deramiocel. Moreover, analysts have revised their earnings downwards for the upcoming period, indicating potential headwinds. However, it's worth noting that the company has had a significant return over the last week and month, with price total returns of 21.53% and 28.28% respectively, showcasing recent positive investor sentiment.
For investors seeking a deeper analysis, there are 12 additional InvestingPro Tips available for Capricor, which can be found at https://www.investing.com/pro/CAPR. These tips provide a comprehensive view of the company's financial status and market expectations, which could be invaluable for making informed investment decisions in the context of the company's recent developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.